$BioXcel Therapeutics (BTAI.US)$ NEWS BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting BioXcel Therapeutics (Nasdaq: BTAI) has announced that Dr. Rob Risinger will present both oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 28 to 31 in Miami Beach, FL. The presentations will focus on the comparison of sublingual Dexmedetomidine wit...
BioXcel Therapeutics股票讨论区
$Iovance Biotherapeutics (IOVA.US)$第 2 阶段
$Supernus Pharmaceuticals (SUPN.US)$第 2a 阶段
$BRANDES INTERNATIONAL ETF (BINV.US)$第 2a 阶段
$MorphoSys (MOR.US)$第 2 阶段
$Nuvation Bio (NUVB.US)$第 2 阶段
$ALX Oncology (ALXO.US)$第 2 阶段
$BioXcel Therapeutics (BTAI.US)$第 2 阶段
$Purple Biotech (PPBT.US)$第 2 阶段
$Arcus Biosciences (RCUS.US)$第 2 阶段
$Medicenna Therapeutics (MDNAF.US)$第 2b 阶段
$Affimed NV (AFMD.US)$第 2 阶段
$Barinthus Biotherapeutics (BRNS.US)$第 2b 阶段...
NEWS
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
BioXcel Therapeutics (Nasdaq: BTAI) has announced that Dr. Rob Risinger will present both oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 28 to 31 in Miami Beach, FL. The presentations will focus on the comparison of sublingual Dexmedetomidine wit...
新闻
BioXcel Therapeutics 宣布了研究者赞助的 BXCL701 和 KEYTRUDA® 治疗转移性胰腺导管腺癌 (PDAC) 的 2 期试验的初步结果的最新摘要,该研究选定在 2024 年 ASCO 年会上发表
关于 BXCL701 和 KEYTRUDA® 治疗转移性胰腺导管腺癌的 2 期试验初步结果的最新摘要已入选在 2024 年 ASCO 年会上发表...
暂无评论